Imagenetix Inc. Signs San Diego Padres Slugger Tony Gwynn and Wife Alicia as Spokespersons.

Business Editors & Health/Sports Writers

SAN DIEGO--(BUSINESS WIRE)--June 13, 2001

San Diego-based Imagenetix Inc. (OTCBB:IAGX), www.imagenetix.net, today announced that eight-time Major League batting champion and right fielder for the San Diego Padres, Tony Gwynn, and wife

Under the terms of the agreement, they will represent both Imagenetix and its Celadrin(TM) products, which are developed and privately labeled by the company.

In his 20 plus years with the San Diego Padres, Gwynn, 41, has undergone multiple knee surgeries. In addition, he has had to overcome pain from bone-on-bone grinding in the knee (from lack of cartilage) and the loss of mobility resulting from multiple injuries, surgeries, and the natural aging process. Since rehabilitation following his last surgery, Gwynn has been on a program of exercise and training.

To provide support for healthy joint function and mobility, Gwynn consumes daily doses of Celadrin(TM) capsules, a natural supplement that is a combination of fatty acid esters. He also topically rubs on Celadrin(TM) cream.

"We feel very fortunate to have put Tony on our Celadrin(TM) products," commented Bill Spencer, president of Imagenetix. "It has been very gratifying to see Tony rely successfully on Celadrin(TM) for joint support."

Said Gwynn: "I feel good. Everyone else is shocked by how well I am running. This is the best my knees have felt in probably five years."

Alicia Gwynn, a power walker, said, "Celadrin(TM) has made a huge difference to both Tony and me."

As a result of their positive experiences with the products, the Gwynns have joined the Imagenetix team as official spokespersons for the company and the Celadrin(TM) products. As compensation, they will receive a cash fee as well as stock options in Imagenetix.

Celadrin(TM) is a new nutritional supplement which can be sold through mass retailers, health and nutrition stores, network marketing companies and other distribution channels. As a nutritional supplement, neither FDA testing or approval is required for sale or purchase of the products. However, Imagenetix chose to subject Celadrin(TM) to a recent clinical study.

On Dec. 13, 2000, the company announced results of its double-blind, multi-center, placebo-controlled trial of Celadrin(TM) (during the trial the product was known as CMC or CM Complex). In the trial, Imagenetix examined the impact that a 60-day oral administration of Celadrin(TM) had on 93 patients. The patients ranged in age from 37 to 77 years. Half the patients received Celadrin(TM), and the remainder received a placebo.